Outpatient treatment of deep vein thrombosis with LMWH

Wiener Medizinische Wochenschrift

Volumn 149, Issue 2-4, 1999, Pages 46-49

  Koopman, Maria M W ^a   Buller W R ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE

Author keywords

Anticoagulation; Deep venous thrombosis; Low molecular weight heparin; Outpatient therapy; Venous thromboembolism

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; OUTPATIENT; PATIENT COUNSELING; PRACTICE GUIDELINE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT PLANNING;

AMBULATORY CARE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; RANDOMIZED CONTROLLED TRIALS; THROMBOPHLEBITIS; TREATMENT OUTCOME;

EID: 0032893822     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. (1) Basu D, Gallus A, Hirsh J, Cade J: A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. New Engl J Med 1972;287:325-327.
2. (2) Brandjes DPM, Heijboer H, Büller HR, et al: Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-1489.
3. (3) den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762.
4. (4) Gallus A, Jackaman J, Tillet J, et al: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986;II:1293-1296.
5. (5) Ginsberg JS: Management of venous thromboembolism. N Engl J Med 1996;335:1816-1828.
6. (6) Harrison L, McGinnis J, Crowther M, et al: Assessment of outpatient treatment of deep vein thrombosis with low-molecular-weight heparin. Arch Int Med 1998;158:2001-2003.
7. (7) Hirsh J, Levine MN: Low molecular weight heparin. Blood 1992; 79:1-17.
8. (8) Hommes DW, Bura A, Mazzolai L, Büller HR, ten Cate JW: Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Int Med 1992;116:279-284.
9. (9) Hull RD, Raskob GE, Rosenbloom D, et al: Heparin for 5 days as compared with 10 days in the initial treatment of proximal-vein thrombosis. N Engl J Med 1990;322:1260-1266.
10. (10) Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, d'Azemar P, Büller HR, on behalf of the Tasman study group: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687.
11. (11) Kuijer PMM, Prins MH, Büller HR: Low molecular-weight heparins: Treatment of venous thromboembolism. In Sasahara AA and Loscalzo J (eds): Advances in therapeutic agents in thrombosis and thrombolysis. New York, Dekker 1997, pp 129-147.
12. (12) Lensing AWA, Hirsh J, Büller HR: Diagnosis of venous thromboembolism. In Colman W, Hirsh J, Marder VJ, Salzman EW (eds): Haemostasis and Thrombosis: basic principles and clinical practice. Philadelphia, Lippincott, 1993, pp 1297-1311.
13. (13) Levine MN, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334:677-681.
14. (14) Prandoni P, Lensing AWA. Büller HR, Cogo et al: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-1133.
15. (15) Svensson PJ, Dahlbäck B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-522.
16. (16) van den Belt AGM, Bossuyt PMM, Prins MH, Gallus AS, Büller HR, on behalf of the Tasman Study Group: Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis. A cost minimisation analysis. Thromb Haemost 1998;79:259-263.
17. (17) Wells PS, Kovacs MJ, Bormanis J, et al: Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin. Arch Int Med 1998;158: 1809-1812.
18. (18) Young E, Prins MH, Levine MN, Hirsh J: Heparin binding to plasma proteins. An important mechanism for heparin resistance. Thromb Haemost 1992;67:639-643.